Susquehanna International Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.05M | Buy |
18,700
+13,200
| +240% | +$860K | ﹤0.01% | 7758 |
|
|
2025
Q4 | $441K | Sell |
5,500
-59,400
| -92% | -$3.99M | ﹤0.01% | 9099 |
|
|
2025
Q3 | $3.16M | Buy |
64,900
+28,600
| +79% | +$1.77M | ﹤0.01% | 4870 |
|
|
2025
Q2 | $2.71M | Buy |
36,300
+3,700
| +11% | +$245K | ﹤0.01% | 5161 |
|
|
2025
Q1 | $2.07M | Sell |
32,600
-104,100
| -76% | -$7.08M | ﹤0.01% | 5461 |
|
|
2024
Q4 | $10.7M | Buy |
136,700
+42,100
| +45% | +$3.38M | ﹤0.01% | 2579 |
|
|
2024
Q3 | $7.6M | Buy |
94,600
+58,700
| +164% | +$4.74M | ﹤0.01% | 2983 |
|
|
2024
Q2 | $2.97M | Buy |
35,900
+17,400
| +94% | +$1.53M | ﹤0.01% | 4325 |
|
|
2024
Q1 | $1.58M | Buy |
18,500
+14,800
| +400% | +$1.16M | ﹤0.01% | 5887 |
|
|
2023
Q4 | $316K | Buy |
+3,700
| New | +$320K | ﹤0.01% | 9721 |
|
|
2023
Q3 | – | Sell |
-11,300
| Closed | -$962K | – | 12378 |
|
|
2023
Q2 | $962K | Buy |
11,300
+8,600
| +319% | +$727K | ﹤0.01% | 6763 |
|
|
2023
Q1 | $223K | Sell |
2,700
-6,500
| -71% | -$526K | ﹤0.01% | 10354 |
|
|
2022
Q4 | $724K | Sell |
9,200
-44,300
| -83% | -$3.56M | ﹤0.01% | 6943 |
|
|
2022
Q3 | $3.96M | Buy |
53,500
+44,700
| +508% | +$3.21M | ﹤0.01% | 3533 |
|
|
2022
Q2 | $574K | Sell |
8,800
-8,200
| -48% | -$485K | ﹤0.01% | 7913 |
|
|
2022
Q1 | $1.07M | Buy |
17,000
+7,300
| +75% | +$397K | ﹤0.01% | 6930 |
|
|
2021
Q4 | $514K | Sell |
9,700
-33,900
| -78% | -$2.07M | ﹤0.01% | 9129 |
|
|
2021
Q3 | $3.08M | Sell |
43,600
-15,400
| -26% | -$972K | ﹤0.01% | 4896 |
|
|
2021
Q2 | $3.93M | Buy |
59,000
+45,000
| +321% | +$3.18M | ﹤0.01% | 4470 |
|
|
2021
Q1 | $1.55M | Sell |
14,000
-6,100
| -30% | -$755K | ﹤0.01% | 6542 |
|
|
2020
Q4 | $2.39M | Buy |
20,100
+12,900
| +179% | +$1.39M | ﹤0.01% | 4732 |
|
|
2020
Q3 | $628K | Sell |
7,200
-4,700
| -39% | -$411K | ﹤0.01% | 7194 |
|
|
2020
Q2 | $1.07M | Sell |
11,900
-16,300
| -58% | -$1.65M | ﹤0.01% | 5776 |
|
|
2020
Q1 | $2.81M | Buy |
28,200
+26,200
| +1,310% | +$2.84M | ﹤0.01% | 3398 |
|
|
2019
Q4 | $230K | Sell |
2,000
-1,300
| -39% | -$157K | ﹤0.01% | 8513 |
|
|
2019
Q3 | $416K | Sell |
3,300
-5,500
| -63% | -$698K | ﹤0.01% | 7673 |
|
|
2019
Q2 | $1.06M | Buy |
8,800
+4,200
| +91% | +$413K | ﹤0.01% | 5513 |
|
|
2019
Q1 | $402K | Buy |
4,600
+200
| +5% | +$18.2K | ﹤0.01% | 6688 |
|
|
2018
Q4 | $440K | Buy |
4,400
+800
| +22% | +$84K | ﹤0.01% | 6280 |
|
|
2018
Q3 | $412K | Buy |
+3,600
| New | +$373K | ﹤0.01% | 6880 |
|
|
2018
Q1 | – | Sell |
-5,700
| Closed | -$331K | – | 9646 |
|
|
2017
Q4 | $331K | Buy |
+5,700
| New | +$300K | ﹤0.01% | 7427 |
|
|
2014
Q2 | – | Sell |
-26,100
| Closed | -$851K | – | 9889 |
|
|
2014
Q1 | $851K | Buy |
+26,100
| New | +$997K | ﹤0.01% | 5791 |
|
Other funds holding HAE
VPM
VCM
RRAM
Susquehanna International Group's HAE Position: Q1 2026 in Review
Susquehanna International Group increased its Haemonetics (HAE) stake by 238% in Q1 2026, buying an estimated $10.7M and bringing the position to 234,271 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2716.
Susquehanna International Group first reported a position in HAE in Q3 2013 and has held it in 41 quarters since. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Susquehanna International Group held 234,271 shares of Haemonetics worth $13.2M as of Q1 2026.
- Susquehanna International Group bought 164,869 Haemonetics shares in Q1 2026, an estimated $10.7M.
- Haemonetics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2716 holding.
- Susquehanna International Group first reported a position in Haemonetics in Q3 2013 and has held it in 41 quarters since.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.